{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:06:35Z","timestamp":1792710395440,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109346"],"award-info":[{"award-number":["JP19ek0109346"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109356"],"award-info":[{"award-number":["JP19ek0109356"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109394"],"award-info":[{"award-number":["JP19ek0109394"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["19FC1007"],"award-info":[{"award-number":["19FC1007"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) is a rare chronic neurological disease, large scale studies to collect continuous clinical data have been difficult to conduct. Therefore, the incidence of comorbidities and drug utilization data remain unknown. When conducting trials to develop new drugs in rare disease such as HAM\/TSP, historical control data obtained from registry studies would be useful, as cohorts in rare disease tend to be small. Long-term follow-up of patients with a chronic disease can also be challenging. In this study, we addressed the following two goals using registry data on patients (<jats:italic>n<\/jats:italic>\u2009=\u2009486) enrolled in the Japanese HAM\/TSP patient registry \u201cHAM-net\u201d from 2012 to 2016: 1) to clarify the epidemiological information of HAM\/TSP such as the incidence of comorbidities and drug utilization and 2) to provide the real-world data on changes in lower limb motor dysfunction.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In HAM-net-registered patients, common comorbidities were fractures, herpes zoster, and uveitis, with incidences of 55.5, 10.4, and 6.5, respectively, per 1000 person-years. Every year, oral steroid treatment was administered in 48.2\u201350.7% of the HAM-net-registered patients and interferon-\u03b1 treatment was used in 2.6\u20133.5% of patients. The median dose of oral prednisolone was low at 5.0\u2009mg\/day. The incidence of fractures and herpes zoster tended to be higher in the steroid-treated group than in the untreated group (fractures: 61.0 vs. 48.3, herpes zoster: 12.7 vs. 8.8, per 1000 person-years). The analysis of chronological change in Osame motor disability score (OMDS) indicated that the mean change in OMDS was +\u20090.20 [95% confidence intervals (CI): 0.14\u20130.25] per year in the one-year observation group (<jats:italic>n<\/jats:italic>\u2009=\u2009346) and\u2009+\u20090.57 (95% CI: 0.42\u20130.73) over four years in the four-year observation group (<jats:italic>n<\/jats:italic>\u2009=\u2009148). Significant deterioration of OMDS was noted in all subgroups with varying steroid use status.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study revealed the incidence of comorbidities and drug utilization data in patients with HAM\/TSP using registry data. Furthermore, this study provided real-world data on chronological changes in lower limb motor dysfunction in patients with HAM\/TSP, indicating the utility of these data as historical controls.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1212-4","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T10:59:06Z","timestamp":1571655546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Real-world clinical course of HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Japan"],"prefix":"10.1186","volume":"14","author":[{"given":"Shuntaro","family":"Tsutsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella L. G.","family":"Coler-Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-0345","authenticated-orcid":false,"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fmicb.2012.00389","volume":"3","author":"Y Yamano","year":"2012","unstructured":"Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis. Front Microbiol. 2012;3:389.","journal-title":"Front Microbiol"},{"key":"1212_CR2","doi-asserted-by":"publisher","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","volume":"1","author":"CR Bangham","year":"2015","unstructured":"Bangham CR, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy\/tropical spastic paraparesis. Nat Rev Dis Primers. 2015;1:15012.","journal-title":"Nat Rev Dis Primers"},{"key":"1212_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","volume":"29","author":"SJ Pocock","year":"1976","unstructured":"Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29:175\u201388.","journal-title":"J Chronic Dis"},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pst.1589","volume":"13","author":"K Viele","year":"2014","unstructured":"Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13:41\u201354.","journal-title":"Pharm Stat"},{"key":"1212_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","volume":"46","author":"S Izumo","year":"1996","unstructured":"Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology. 1996;46:1016\u201321.","journal-title":"Neurology."},{"key":"1212_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1742-4690-3-63","volume":"3","author":"GP Taylor","year":"2006","unstructured":"Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T-Lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63.","journal-title":"Retrovirology."},{"key":"1212_CR7","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/jnnp.2009.191239","volume":"81","author":"F Martin","year":"2010","unstructured":"Martin F, Fedina A, Youshya S, Taylor GP. A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK. J Neurol Neurosurg Psychiatry. 2010;81:1336\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","volume":"63","author":"S Olindo","year":"2006","unstructured":"Olindo S, Cabre P, Lezin A, Merle H, Saint-Vil M, Signate A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol. 2006;63:1560\u20136.","journal-title":"Arch Neurol"},{"key":"1212_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-016-0451-x","volume":"11","author":"AL Coler-Reilly","year":"2016","unstructured":"Coler-Reilly AL, Yagishita N, Suzuki H, Sato T, Araya N, Inoue E, et al. Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J Rare Dis. 2016;11:69.","journal-title":"Orphanet J Rare Dis"},{"key":"1212_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3389\/fmicb.2018.01651","volume":"9","author":"T Sato","year":"2018","unstructured":"Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, et al. Proposal of classification criteria for HTLV-1-associated myelopathy\/tropical spastic paraparesis disease activity. Front Microbiol. 2018;9:1651.","journal-title":"Front Microbiol"},{"key":"1212_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006304","volume":"12","author":"S Olindo","year":"2018","unstructured":"Olindo S, Jeannin S, Saint-Vil M, Signate A, Edimonana-Kaptue M, Joux J, et al. Temporal trends in human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) incidence in Martinique over 25 years (1986-2010). PLoS Negl Trop Dis. 2018;12:e0006304.","journal-title":"PLoS Negl Trop Dis"},{"key":"1212_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s13311-017-0533-z","volume":"14","author":"ALG Coler-Reilly","year":"2017","unstructured":"Coler-Reilly ALG, Sato T, Matsuzaki T, Nakagawa M, Niino M, Nagai M, et al. Effectiveness of daily prednisolone to slow progression of human T-lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis: a multicenter retrospective cohort study. Neurotherapeutics. 2017;14:1084\u201394.","journal-title":"Neurotherapeutics."},{"key":"1212_CR13","first-page":"271","volume":"3","author":"M Osame","year":"1990","unstructured":"Osame M, Igata A, Matsumoto M, Kohka M, Usuku K, Izumo S. HTLV-I-associated myelopathy (HAM) treatment trials, retrospective survey and clinical and laboratory findings. Hematol Rev. 1990;3:271\u201384.","journal-title":"Hematol Rev"},{"key":"1212_CR14","first-page":"345","volume":"2","author":"M Nakagawa","year":"1996","unstructured":"Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/ tropical spastic paraparesis. J Neuro-Oncol. 1996;2:345\u201355.","journal-title":"J Neuro-Oncol"},{"key":"1212_CR15","first-page":"50","volume":"1","author":"M Nakagawa","year":"1995","unstructured":"Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neuro-Oncol. 1995;1:50\u201361.","journal-title":"J Neuro-Oncol"},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1590\/S0037-86822009000600004","volume":"42","author":"RH Rathsam-Pinheiro","year":"2009","unstructured":"Rathsam-Pinheiro RH, Boa-Sorte N, Castro-Lima-Vargens C, Pinheiro CA, Castro-Lima H, Galvao-Castro B. Ocular lesions in HTLV-1 infected patients from Salvador, state of Bahia: the city with the highest prevalence of this infection in Brazil. Rev Soc Bras Med Trop. 2009;42:633\u20137.","journal-title":"Rev Soc Bras Med Trop"},{"key":"1212_CR17","first-page":"327","volume":"102","author":"E Ikeda","year":"1998","unstructured":"Ikeda E, Ono A, Hikita N, Arima K, Mochizuki M, Yamaguchi K, et al. Estimated prevalence rate of HTLV-I uveitis in Chikugo. Nippon Ganka Gakkai Zasshi. 1998;102:327\u201332.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1212_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/14397595.2013.843765","volume":"24","author":"H Tsuboi","year":"2014","unstructured":"Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, et al. Primary and secondary surveys on the epidemiology of Sjogren's syndrome in Japan. Mod Rheumatol. 2014;24:464\u201370.","journal-title":"Mod Rheumatol"},{"key":"1212_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12891-015-0773-1","volume":"16","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Shimizu T, Takagi Y, Takahashi Y, Horai Y, Nakashima Y, et al. Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjogren's syndrome. BMC Musculoskelet Disord. 2015;16:335.","journal-title":"BMC Musculoskelet Disord"},{"key":"1212_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/14397595.2013.854059","volume":"24","author":"H Yamanaka","year":"2014","unstructured":"Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24:33\u201340.","journal-title":"Mod Rheumatol"},{"key":"1212_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/art.1780390314","volume":"39","author":"K Eguchi","year":"1996","unstructured":"Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39:463\u20136.","journal-title":"Arthritis Rheum"},{"key":"1212_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.55.3.193","volume":"55","author":"S Motokawa","year":"1996","unstructured":"Motokawa S, Hasunuma T, Tajima K, Krieg AM, Ito S, Iwasaki K, et al. High prevalence of arthropathy in HTLV-I carriers on a Japanese island. Ann Rheum Dis. 1996;55:193\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1212_CR23","first-page":"298","volume":"34","author":"N Toyama","year":"2013","unstructured":"Toyama N, Shiraki K. Epidemiological studies on varicella zoster in Miyazaki Prefecture. Infectious Agents Surveillance Report (IASR). 2013;34:298\u2013300.","journal-title":"Infectious Agents Surveillance Report (IASR)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1212-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T23:26:42Z","timestamp":1603150002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1212-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"22 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of St. Marianna University School of Medicine (# 2044). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}